Molina Healthcare price target raised to $202 from $180 at UBS

UBS raised the firm’s price target on Molina Healthcare (MOH) to $202 from $180 and keeps a Neutral rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected Q1 results benefited from favorable respiratory trends and seasonal cost patterns, while improved Medicare Advantage rates, steadier ACA exchange enrollment, and modest Medicaid outperformance have boosted confidence in margin recovery despite ongoing cost pressures from specialty drugs, GLP-1s, and behavioral health, the analyst tells investors in a research note.